Matsumoto, Kazuaki



Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 (Shiba-Kyoritsu)



Career 【 Display / hide

  • 2003.04

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 医療職員

  • 2007.04

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 主任

  • 2014.04

    慶應義塾大学薬学部, 実務薬学講座, 准教授

  • 2017.04

    慶應義塾大学薬学部, 薬効解析学講座, 教授

Academic Background 【 Display / hide

  • 1994.04

    Kumamoto University, 薬学部, 薬学科

    University, Graduated

  • 1998.04

    Kumamoto University, 薬学研究科

    Graduate School, Completed, Master's course

  • 2000.04

    Kumamoto University, 薬学研究科

    Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide

  • 博士(薬学), Kumamoto University, Coursework, 2003.03


Licenses and Qualifications 【 Display / hide

  • 薬剤師免許証, 1998.07

  • 日本薬剤師研修センター認定薬剤師, 2006.03

  • 日本医療薬学会認定薬剤師, 2009.01

  • インフェクションコントロールドクター, 2009.01

  • 感染制御専門薬剤師, 2009.03

display all >>


Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy

Research Keywords 【 Display / hide

  • Drug Delivery System

  • 抗菌化学療法

  • 高齢者医療

Research Themes 【 Display / hide

  • 医薬品の薬効評価と副作用解析に基づいた薬物療法の最適化に関する研究, 



Books 【 Display / hide

  • ケースで学ぶ老年薬学

    松元一明, 日経BP, 2024.01

    Scope: 感染症.

  • 今日の治療薬2024

    松元一明, 南江堂, 2024.01

  • 今日の治療指針2024

    松元一明, 医学書院, 2024.01

    Scope: 市中肺炎/急性中耳炎 服薬指導・薬剤情報

  • マナビジュアルノート 感染症・病原体とくすり

    松元一明, 南山堂, 2023.12

  • 薬がみえる vol 3 第2版

    松元一明, メディックメディア, 2023.09

    Scope: 抗菌薬/細胞壁合成阻害薬.

display all >>

Papers 【 Display / hide

  • Efficacy of hemodialysis and plasma exchange for ceftriaxone-induced antibiotic-associated encephalopathy:A case report of severe acute kidney injury due to rapidly progressive glomerulonephritis

    Nagayama Shohei, Tashiro Sho, Kawai Yuki, Kunii Ayana, Baba Kenji, Kawasaki Keiko, Komiya Shiro, Yuto Jun, Matsumoto Kazuaki, Iwamoto Tamio, Tamura Kouichi

    Nihon Toseki Igakkai Zasshi (The Japanese Society for Dialysis Therapy)  57 ( 2 ) 93 - 98 2024

    Joint Work,  ISSN  13403451

     View Summary

    <p>An 88-year-old woman was admitted to our hospital with a diagnosis of acute kidney injury (AKI, stage 3) in May 20XX, attributed to rapidly progressive glomerulonephritis caused by anti-glomerular basement membrane disease. Emergent hemodialysis (HD) was performed for the rapidly progressing AKI, and she was also treated with PSL combined with plasma exchange (PE). On the fifth day of hospitalization, she showed a decreased level of consciousness. We suspected antibiotic-associated encephalopathy (AAE) due to ceftriaxone (CTRX), which had been administered since admission. The next day, plasma CTRX concentration was high (198.7 μg/mL). We discontinued CTRX. We predicted that PE would promote the removal of CTRX due to its low distribution volume and high protein-binding affinity rate;however, plasma CTRX concentration did not decrease after PE. Although a temporary decrease in plasma CTRX concentration was observed after HD, effective drug elimination was not achieved the next day due to redistribution of the drug from the tissue to the blood (rebound phenomenon). After discontinuation of CTRX, the patientʼs level of consciousness improved to the same level as on admission on the 13th day. Hypoalbuminemia and the presence of the rapidly progressing AKI in the present patient may have led to a decrease in the protein-binding affinity rate of CTRX, resulting in the plasma CTRX concentration being unchanged after HD and PE. As elderly AKI patients have multiple risks for AAE, we need to take this background into account.</p>

  • Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E).

    Namiki T, Yokoyama Y, Hashi H, Oda R, Jibiki A, Kawazoe H, Matsumoto K, Suzuki S, Nakamura T

    Pharmacotherapy (Pharmacotherapy)  44 ( 2 ) 149 - 162 2023.11

    Joint Work,  ISSN  0277-0008

     View Summary

    Study Objective: Establish methods for measuring cefmetazole (CMZ) concentrations conduct a pharmacokinetic/pharmacodynamic (PK/PD) analysis using unbound CMZ concentrations for extended-spectrum β-lactamase producing enterobacterales (ESBL-E) and investigate optimal dosing regimens for not undergoing hemodialysis (non-HD) and undergoing hemodialysis (HD) patients. Design: Prospective observational study. Patients: Included patients treated with CMZ who provided written informed consent and were admitted to the Tokyo Bay Urayasu Ichikawa Medical Center between August 2021 and July 2022. Measurements: Total and Unbound CMZ concentration was measured by high-performance liquid chromatography (HPLC) with solid-phase extraction and ultrafiltration. Setting: Determining the CMZ dosing regimen involved modified creatinine clearance (CLCR) with measured body weight (BW) using the Cockcroft–Gault equation. For non-HD patients, blood samples were collected during at least three points. For patients undergoing HD, 1 g was administered via intravenous infusion, or rapid intravenous injection after HD, or 30 min before the end of HD. Blood samples were collected before HD (pre-HD), and 1 and 3 h after starting HD and post-HD. All blood samples were collected at steady-state. Patient information was collected from electronic medical records. An unbound PK model was constructed for the non-HD patients. A nomogram was constructed using Monte Carlo simulations with a 90% probability of target attainment at 70% free time above the minimum inhibitory concentration (MIC). For the HD patients, a nomogram was used to determine the optimal dosing regimen for each HD schedule. Main Results: CMZ measurement methods were established. A model analysis of unbound PK in 37 non-HD patients incorporated creatinine clearance (CLCR) using the Cockcroft–Gault equation, albumin (ALB) for clearance and body weight (BW) for the volume of distribution. In Monte Carlo simulations, nomograms corresponding to the MIC (known and unknown) were generated for each covariate. Using the nomogram, non-HD patients with an ESBL-E MIC of 8 mg/L, a BW of 60 kg, an ALB of 25 g/L, and a CLCR of 60 mL/min required administration of 2 g every 6 h (1- and 3-h infusions). Unbound PK model parameters were calculated for 7 HD patients, and the optimal dosing regimens following PK/PD were determined for each HD schedule. In HD patients, the regimen after and during HD was established using a treatment that was effective up to an ESBL-E MIC of 4 mg/L. Conclusions: The nomogram for CMZ regimens established by PK/PD analysis of measured CMZ concentrations enables optimal CMZ dosing for ESBL-E-infected patients.

  • Elucidating the binding properties of methemoglobin in red blood cell to cyanide, hydrosulfide, and azide ions using artificial red blood cell.

    Suzuki Y, Arakida Y, Sakai H, Enoki Y, Matsumoto K, Taguchi K

    Toxicology and applied pharmacology (Toxicology and Applied Pharmacology)  481   116752 2023.11

    Joint Work,  ISSN  0041-008X

     View Summary

    Methemoglobin (metHb), the oxidized form of hemoglobin, lacks the ability of reversible oxygen binding; however, it has a high binding affinity to toxic substances such as cyanide, hydrosulfide, and azide. This innate property of metHb offers the clinical option to treat patients poisoned with these toxins, by oxidizing the endogenous hemoglobin in the red blood cells (RBCs). The binding properties of naked metHb (isolated from RBC) with these toxins has been studied; however, the binding behaviors of metHb under the intracellular conditions of RBC are unclear because of the difficulty in detecting metHb status changes in RBC. This study aimed to elucidate the binding properties of metHb in RBC under physiological and poisoned conditions using artificial RBC, which was hemoglobin encapsulated in a liposome. The mimic-circumstances of metHb in RBC (metHb-V) was prepared by oxidizing the hemoglobin in artificial RBC. Spectroscopic analysis indicated that the metHb in metHb-V exhibited a binding behavior different from that of naked metHb, depending on the toxic substance: When the pH decreased, (i) the cyanide binding affinity of metHb-V remained unchanged, but that of naked metHb decreased (ii) the hydrosulfide binding affinity was increased in metHb-V but was decreased in naked metHb. (iii) Azide binding was increased in metHb-V, which was similar to that in naked metHb, irrespective of the pH change. Thus, the binding behavior of intracellular metHb in the RBC with cyanide, hydrosulfide, and azide under physiological and pathological conditions were partly elucidated using the oxidized artificial RBC.

  • A cohort study of the risk factors and the target AUC to avoid vancomycin-associated acute kidney injury in pediatric patients.

    Kanazawa N, Shigemi A, Amadatsu N, Arimura K, Shimono S, Oda K, Chuang VTG, Matsumoto K, Kawamura H, Terazono H

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (Journal of Infection and Chemotherapy)  30 ( 4 ) 323 - 328 2023.11

    Joint Work,  ISSN  1341-321X

     View Summary

    Objectives: In recent years, Vancomycin (VCM) dosing design using area under the concentration-time curve (AUC) has been recommended as a measure of efficacy and safety, but there are fewer reports on pediatric patients than on adults. In this study, we evaluated the threshold of AUC for AKI occurrence in pediatric patients and investigated the factors that contribute to the occurrence of AKI. Methods: Pediatric patients aged 1–15 years on VCM treatment who underwent TDM at Kagoshima University Hospital from April 2016 to March 2022 were included in the computation of AUC using pediatric population pharmacokinetic parameters. Results: The ROC curve showed that the AUC threshold for the risk of developing AKI was 583.0 μg・h/mL, and the AUC-ROC curve was 0.873 (sensitivity 0.930, specificity 0.750). Univariate analysis showed that factors associated with AKI incidence were the duration of VCM administration, ICU admission, and AUCSS. Concomitant medications identified as risk factors for AKI incidence were tazobactam/piperacillin, liposomal amphotericin B, calcineurin inhibitors, contrast agents, and H2-receptor blockers. The multivariate analysis showed that AUC ≧ 583.0 μg・h/mL (odds ratio 20.14, 95% CI 3.52–115.22, p < 0.001) and H2-receptor blockers (odds ratio 8.70, 95% confidence interval = 1.38–54.87, p = 0.02) were independent factors for AKI incidence. Conclusions: We showed that in pediatric patients receiving VCM, the risk of AKI increases as AUC increases. The findings imply that concurrent use of VCM and H2-receptor blockers may increase the risk of AKI.

  • Flowchart for predicting achieving the target area under the concentration-time curve of vancomycin in critically ill Japanese patients: A multicenter retrospective study.

    Ishigo T, Fujii S, Ibe Y, Aigami T, Nakano K, Fukudo M, Yoshida H, Tanaka H, Ebihara F, Maruyama T, Hamada Y, Suzuki A, Fujihara H, Yamaguchi F, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Matsumoto K

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (Journal of Infection and Chemotherapy)  30 ( 4 ) 329 - 336 2023.11

    Joint Work,  ISSN  1341-321X

     View Summary

    Introduction: In therapeutic drug monitoring (TDM) of vancomycin (VCM), the area under the concentration-time curve (AUC) is related to the clinical efficacy and toxicity. Therefore, herein, we examined the factors associated with achieving the target AUC at follow-up and developed a decision flowchart for achieving the target AUC in critically ill patients. Methods: This multicenter retrospective observational study was conducted at eight hospitals. We retrospectively analyzed data from patients who had received VCM in the intensive care unit from January 2020 to December 2022. Decision-tree (DT) analysis was performed using factors with p < 0.1 in univariate analysis as the independent variables. Case data were split up to two times, and four subgroups were included. The primary endpoint was achieving the target AUC at the follow-up TDM (AUCfollow-up) and target AUCfollow-up achievement was defined as an AUC of 400–600 μg‧h/mL. The initial AUC values were calculated with the 2-point concentrations (peak and trough) using the Bayesian estimation software Practical AUC-guided TDM (PAT). Results: Among 70 patients (median age [interquartile range], 66 [56, 79] years; 50 % women), the AUCfollow-up was achieved in 70 % (49/70). Three factors were selected for the decision flow chart: predicted AUCfollow-up of 400–600 μg‧h/mL, dosing at 12-h intervals, and CCr of 130 mL/min/1.73 m2 or higher; the accuracy was adequate (92 %, R2 0.52). Conclusion: We successfully identified the factors associated with achieving the target AUC of VCM at follow-up TDM and developed a simple-to-use DT model. However, the validity of the findings needs to be evaluated.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • 同種造血幹細胞移植後にポサコナゾール腸溶錠の血中濃度が低値を示した一例

    島村 千陽, 坂本 靖宜, 長谷川 拓也, 榎木 裕紀, 田口 和明, 松元 一明

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 116 - 116 2024.01

    ISSN  1340-7007

  • バンコマイシン投与で2点採血を実施した患者における1点採血と2点採血の比較

    鈴木 絢子, 佐村 優, 石郷 友之, 伊部 裕太, 相神 智宏, 吉田 博昭, 田中 宏明, 海老原 文哉, 丸山 拓実, 南雲 史雄, 小松 敏彰, 冨澤 淳, 千葉 博暁, 詫間 章俊, 榎木 裕紀, 田口 和明, 浜田 幸宏, 西 圭史, 藤居 賢, 松元 一明, 山口 史博, 藤原 久登

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 109 - 109 2024.01

    ISSN  1340-7007

  • デキストラン硫酸ナトリウム誘発性炎症性腸疾患マウスモデルを用いたfidaxomicinとvancomycinの抗炎症効果比較

    三原 貴之, 榎木 裕紀, 田口 和明, 松元 一明

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 95 - 95 2024.01

    ISSN  1340-7007

  • Mycobacterium avium complexに対するβ-ラクタム系抗菌薬2剤併用の有効性評価

    吉川 万衣子, 西村 知泰, 三澤 可奈, 島村 莉奈, 榎木 裕紀, 田口 和明, 松元 一明, 長谷川 直樹

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 97 - 98 2024.01

    ISSN  1340-7007

  • Mycobacterium abscessusのコロニー形態は抗菌薬濃度によって変化する

    島村 莉奈, 西村 知泰, 三澤 可奈, 吉川 万衣子, 榎木 裕紀, 田口 和明, 松元 一明, 長谷川 直樹

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 1 ) 98 - 98 2024.01

    ISSN  1340-7007

display all >>

Presentations 【 Display / hide

  • 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築.


    第44回日本臨床薬理学会学術総会 (兵庫県) , 


    Oral presentation (general)

  • 第2部:抗微生物薬の選択と投与「TDMガイドラインのupdate」


    敗血症WEBセミナー2023 微生物との対峙 (東京都) , 


    Public lecture, seminar, tutorial, course, or other speech

  • 抗菌薬投与によるMycobacterium abscessusのコロニー形態変化.


    第54回結核・非定型抗酸菌症治療研究会 (東京都) , 


    Oral presentation (general)

  • Mycobacterium abscessus complexに対してナキュバクタムとβラクタム系薬2剤併用は有効である.


    第54回結核・非定型抗酸菌症治療研究会 (東京都) , 


    Oral presentation (general)

  • 薬剤感受性試験によるMycobacterium avium complexに対するβ-ラクタム系抗菌薬2剤併用の有効性評価.


    第54回結核・非定型抗酸菌症治療研究会 (東京都) , 


    Oral presentation (general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 新規肺MABC症治療薬の開発と革新的非臨床PK/PD評価法の構築


    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • 薬剤耐性淋菌・緑膿菌に有効な新規抗菌剤の開発


    国立研究開発法人日本医療研究開発機構(AMED), 新興・再興感染症に対する革新的医薬品等開発推進研究事業, Joint research, Coinvestigator(s)

  • ホローファイバー感染モデルを用いたカルバペネム耐性菌感染症の抗菌薬併用療法に関する橋渡し研究


    国立研究開発法人国立国際医療研究センター, 国際医療研究開発事業, Joint research, Coinvestigator(s)

  • マウス肺感染モデルを用いたOP0595の臨床有効性予測


    Meiji Seikaファルマ株式会社, Commissioned research, Principal investigator

  • Investigation of the effectiveness of imeglimin as a potential therapeutic agent for sarcopenia


    大日本住友製薬株式会社, Commissioned research, Principal investigator

display all >>

Intellectual Property Rights, etc. 【 Display / hide

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Date applied: 特願2020-144044  2020.08 

    Patent, Joint

Awards 【 Display / hide

  • 第44回日本臨床薬理学会学術総会優秀発表賞

    並木孝哉、横山雄太、枦秀樹、織田錬太郎、地引綾、河添仁、松元一明、鈴木小夜、中村智徳., 2023.12, 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築.

  • 第17回日本腎臓病薬物療法学会学術集会・総会2023優秀演題賞

    石郷友之、藤居賢、伊部裕太、吉田博昭、田中宏明、海老原文哉、丸山拓実、鈴木絢子、佐村優、南雲史雄、小松敏彰、冨澤淳、詫間章俊、千葉博暁、榎木裕紀、田口和明、浜田幸宏、西圭史、松元一明、福土将秀., 2023.10,  ICU症例におけるバンコマイシンの急性腎障害と早期AUCとの関連性.

  • 日本薬学会第143年会 学生優秀発表賞 口頭発表の部

    長邑花, 榎木裕紀, 田口和明, 松元一明., 2023.04, 骨格筋萎縮による敗血症病態の増悪と免疫状態変動の関与.

  • 第14回日本化学療法学会東日本支部 支部長賞(基礎)

    田代渉、榎木裕紀、田口和明、松元一明, 2023.01, Clostridioides difficileに対するfidaxomicinのin vitro抗菌活性評価及びin vivo感染マウスモデルを用いた糞中PK/PD評価

  • 第29回日本血液代替物学会年次大会学生講演賞

    伊藤千尋、田口和明、山田大雅、榎木裕紀、小松晃之、松元一明, 2022.12, ドキソルビシン担持一酸化炭素結合型ヘモグロビン-アルブミンクラスターの創製と抗腫瘍効果の評価

display all >>


Courses Taught 【 Display / hide











display all >>


Social Activities 【 Display / hide

Memberships in Academic Societies 【 Display / hide

  • 日本医真菌学会, 

  • 日本DDS学会, 

  • 日本臨床微生物学会, 

  • 日本老年薬学会 理事・評議員, 

  • 日本薬剤学会, 


display all >>